Revance announces CMS assigns permanent J-code for Daxxify

Revance announced that the U.S. Centers for Medicare & Medicaid Services, or CMS, has assigned a permanent J-code for Daxxify, indicated for the treatment of cervical dystonia in adults. J-Codes are product-specific reimbursement codes used by commercial insurance plans, Medicare, and other government payers and are intended to simplify reimbursement for providers and expand access for patients. The company also announced the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology, the medical journal of the American Academy of Neurology. The study evaluated the safety, duration of response, and efficacy of two doses of Daxxify for the treatment of cervical dystonia and served as the foundation for FDA approval of Daxxify for the treatment of cervical dystonia in August 2023.